GlassScriptPhysician profile
Michael Madievsky
NPI 1982696613
$23,322.52
in general payments reported to CMS, 2019-2025
35 companies · $4,141 in 2025
The $4,141 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,724 · 2020: $1,174 · 2021: $2,862 · 2022: $4,274 · 2023: $4,071 · 2024: $5,076 · 2025: $4,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,035.66 |
| Education | $252.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,045.62 | 2019-2025 | |
| Janssen Biotech, INC. | $3,070.35 | 2019-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $1,807.23 | 2019-2025 | Vemlidy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,632.14 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,563.17 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Ardelyx, INC. | $1,222.00 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $817.14 | 2022-2025 | Dupixent |
| Genzyme Corporation | $755.48 | 2022-2025 | |
| Celgene Corporation | $607.59 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $577.79 | 2019-2022 | |
| Pfizer INC. | $563.75 | 2019-2025 | |
| Madrigal Pharmaceuticals | $501.16 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $378.86 | 2019-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $343.68 | 2024-2025 | Iqirvo |
| Lilly USA, LLC | $340.02 | 2023-2024 | Omvoh, Taltz |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $325.53 | 2024-2025 | Zymfentra, Vegzelma |
| Phathom Pharmaceuticals, INC. | $261.37 | 2024-2025 | Voquezna |
| Amgen INC. | $242.29 | 2022-2023 | Avsola |
| Intercept Pharmaceuticals, INC. | $223.72 | 2019-2025 | Ocaliva |
| Redhill Biopharma INC. | $190.83 | 2020-2024 | Talicia |
| Evoke Pharma, INC. | $124.30 | 2022-2023 | Gimoti |
| E.R. Squibb & Sons, L.L.C. | $120.36 | 2021 | |
| Merck Sharp & Dohme LLC | $118.93 | 2021-2023 | Dificid |
| Aimmune Therapeutics, INC. | $113.49 | 2025 | Vowst |
| Lucid Diagnostics INC. | $67.15 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $56.22 | 2022 | |
| Alnylam Pharmaceuticals INC. | $48.16 | 2021-2022 | |
| Qol Medical, LLC | $46.81 | 2024 | Sucraid |
| Allergan, INC. | $29.73 | 2019 | |
| Alfasigma USA, INC. | $27.53 | 2020 | |
| Shield Therapeutics INC | $25.29 | 2023 | Accrufer |
| Concordia Pharmaceuticals INC. | $20.05 | 2019 | |
| Capsovision, INC. | $19.23 | 2025 | Capsocam Plus |
| Medtronic, INC. | $19.11 | 2023 | Gi Genius |
| Shire North American Group INC | $16.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Madievsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.